This also suggests JAK2 inhibitors may also be an effective precision medicine strategy for CRLF2r/JAK2-mutant ALL, but more clinically relevant in vivo models of CRLF2r/JAK2-mutant ALL, that include human TSLP, are required to assess their efficacy. This evidence concerns the gene TSLP and acute lymphoblastic leukemia.